GlassScriptPhysician profile
Danielle Gooden Gullette
NPI 1821764440
$5,879.14
in general payments reported to CMS, 2019-2025
22 companies · $2,901 in 2025
The $2,901 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.00 · 2022: $580 · 2023: $1,011 · 2024: $1,353 · 2025: $2,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,198 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,198.33 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,457.62 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,173.89 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $585.99 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.88 | 2022-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Insmed, INC. | $394.17 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $308.16 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $249.85 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $241.75 | 2023-2025 | Opsumit, Uptravi |
| Viatris Specialty LLC | $201.91 | 2025 | Yupelri |
| Grifols USA, LLC | $175.66 | 2025 | Prolastin-C Liquid |
| Inogen, INC. | $116.13 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Baxter Healthcare | $111.45 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $83.06 | 2025 | |
| Amgen INC. | $52.00 | 2024 | Tezspire |
| Philips North America LLC | $48.84 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $46.81 | 2021-2024 | Yupelri |
| Itamar Medical INC | $20.12 | 2025 | Watchpatone |
| Takeda Pharmaceuticals U.S.A., INC. | $19.87 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.31 | 2025 | Nuzyra |
| Ethicon INC. | $17.98 | 2025 | Monarch Platform |
| Celgene Corporation | $16.83 | 2024 | Reblozyl |
| Mallinckrodt Hospital Products INC. | $15.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Gullette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.